137 related articles for article (PubMed ID: 36774655)
41. Design of Potent and Selective Covalent Inhibitors of Bruton's Tyrosine Kinase Targeting an Inactive Conformation.
Pulz R; Angst D; Dawson J; Gessier F; Gutmann S; Hersperger R; Hinniger A; Janser P; Koch G; Revesz L; Vulpetti A; Waelchli R; Zimmerlin A; Cenni B
ACS Med Chem Lett; 2019 Oct; 10(10):1467-1472. PubMed ID: 31620235
[TBL] [Abstract][Full Text] [Related]
42. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer.
Carmi C; Mor M; Petronini PG; Alfieri RR
Biochem Pharmacol; 2012 Dec; 84(11):1388-99. PubMed ID: 22885287
[TBL] [Abstract][Full Text] [Related]
43. An Irreversible Inhibitor of HSP72 that Unexpectedly Targets Lysine-56.
Pettinger J; Le Bihan YV; Widya M; van Montfort RL; Jones K; Cheeseman MD
Angew Chem Int Ed Engl; 2017 Mar; 56(13):3536-3540. PubMed ID: 28225177
[TBL] [Abstract][Full Text] [Related]
44. Lysine-Targeting Reversible Covalent Inhibitors with Long Residence Time.
Reja RM; Wang W; Lyu Y; Haeffner F; Gao J
J Am Chem Soc; 2022 Jan; 144(3):1152-1157. PubMed ID: 35040658
[TBL] [Abstract][Full Text] [Related]
45. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
46. Identification of Noncatalytic Lysine Residues from Allosteric Circuits via Covalent Probes.
Bongard J; Lorenz M; Vetter IR; Stege P; Porfetye AT; Schmitz AL; Kaschani F; Wolf A; Koch U; Nussbaumer P; Klebl B; Kaiser M; Ehrmann M
ACS Chem Biol; 2018 May; 13(5):1307-1312. PubMed ID: 29658704
[TBL] [Abstract][Full Text] [Related]
47. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.
Uitdehaag JCM; de Man J; Willemsen-Seegers N; Prinsen MBW; Libouban MAA; Sterrenburg JG; de Wit JJP; de Vetter JRF; de Roos JADM; Buijsman RC; Zaman GJR
J Mol Biol; 2017 Jul; 429(14):2211-2230. PubMed ID: 28539250
[TBL] [Abstract][Full Text] [Related]
48. Selective Covalent Inhibition of "Allosteric Cys121" Distort the Binding of PTP1B Enzyme: A Novel Therapeutic Approach for Cancer Treatment.
Khan S; Bjij I; Soliman MES
Cell Biochem Biophys; 2019 Sep; 77(3):203-211. PubMed ID: 31446553
[TBL] [Abstract][Full Text] [Related]
49. Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors.
Olgen S
Anticancer Agents Med Chem; 2016; 16(8):992-1002. PubMed ID: 26902603
[TBL] [Abstract][Full Text] [Related]
50. Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites.
Olp MD; Sprague DJ; Goetz CJ; Kathman SG; Wynia-Smith SL; Shishodia S; Summers SB; Xu Z; Statsyuk AV; Smith BC
ACS Chem Biol; 2020 Apr; 15(4):1036-1049. PubMed ID: 32149490
[TBL] [Abstract][Full Text] [Related]
51. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
[TBL] [Abstract][Full Text] [Related]
52. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
Singh J; Dobrusin EM; Fry DW; Haske T; Whitty A; McNamara DJ
J Med Chem; 1997 Mar; 40(7):1130-5. PubMed ID: 9089334
[TBL] [Abstract][Full Text] [Related]
53. A new family of covalent inhibitors block nucleotide binding to the active site of pyruvate kinase.
Morgan HP; Walsh MJ; Blackburn EA; Wear MA; Boxer MB; Shen M; Veith H; McNae IW; Nowicki MW; Michels PA; Auld DS; Fothergill-Gilmore LA; Walkinshaw MD
Biochem J; 2012 Nov; 448(1):67-72. PubMed ID: 22906073
[TBL] [Abstract][Full Text] [Related]
54. BTK-inhibitor drug covalent binding to lysine in human serum albumin using LC-MS/MS.
Muste C; Gu C
Drug Metab Pharmacokinet; 2022 Feb; 42():100433. PubMed ID: 34896750
[TBL] [Abstract][Full Text] [Related]
55. Properties of FDA-approved small molecule protein kinase inhibitors.
Roskoski R
Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
[TBL] [Abstract][Full Text] [Related]
56. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
57. Prolonged and tunable residence time using reversible covalent kinase inhibitors.
Bradshaw JM; McFarland JM; Paavilainen VO; Bisconte A; Tam D; Phan VT; Romanov S; Finkle D; Shu J; Patel V; Ton T; Li X; Loughhead DG; Nunn PA; Karr DE; Gerritsen ME; Funk JO; Owens TD; Verner E; Brameld KA; Hill RJ; Goldstein DM; Taunton J
Nat Chem Biol; 2015 Jul; 11(7):525-31. PubMed ID: 26006010
[TBL] [Abstract][Full Text] [Related]
58. Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity.
Gower CM; Thomas JR; Harrington E; Murphy J; Chang ME; Cornella-Taracido I; Jain RK; Schirle M; Maly DJ
ACS Chem Biol; 2016 Jan; 11(1):121-31. PubMed ID: 26505072
[TBL] [Abstract][Full Text] [Related]
59. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
60. A simple method for developing lysine targeted covalent protein reagents.
Gabizon R; Tivon B; Reddi RN; van den Oetelaar MCM; Amartely H; Cossar PJ; Ottmann C; London N
Nat Commun; 2023 Dec; 14(1):7933. PubMed ID: 38040731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
